PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18066703-3 2007 High response rates and limb salvage rates have been reported in multicenter trials, which combined ILP with TNF-alpha plus melphalan, which resulted in the approval of TNF-alpha for this indication in Europe in 1998. Melphalan 124-133 tumor necrosis factor Homo sapiens 169-178 29022281-10 2017 Similar unadjusted ORRs were noted in the melphalan treatment groups with and without TNFalpha (72.0 and 67.0%, respectively; p = 0.27). Melphalan 42-51 tumor necrosis factor Homo sapiens 86-94 22674435-8 2013 CONCLUSIONS: ILP with L19-TNF had a favorable safety and a promising activity profile at a dose of 650 microg of L19-TNF, supporting the exploration of higher L19-TNF doses and a Phase II trial comparing L19-TNF ILP with standard melphalan-containing ILP. Melphalan 230-239 tumor necrosis factor Homo sapiens 117-120 20429035-9 2010 CONCLUSIONS: In the case of locally advanced disease, the addition of low-dose TNF to melphalan-based isolated limb perfusion appears safe and particularly useful. Melphalan 86-95 tumor necrosis factor Homo sapiens 79-82 16462850-4 2006 High response rates and limb-salvage rates have been reported in multicenter trials that combined ILP with TNF-alpha plus melphalan; these trials resulted in the approval of TNF-alpha for bulky melanoma metastases and soft tissue sarcomas in Europe in 1998. Melphalan 122-131 tumor necrosis factor Homo sapiens 174-183 16767914-3 2003 Recently, Tumor Necrosis Factor (TNFalpha) has been employed at high dosages (3-4 mg) in association to Melphalan and hyperthermia. Melphalan 104-113 tumor necrosis factor Homo sapiens 10-31 16025434-5 2005 This early activation was followed by elevated levels of tumor necrosis factor (TNF)-alpha mRNA within 2 h. We also observed increased expression of intercellular adhesion molecule-1 (ICAM-1) on the surface of both cell lines 18 h after exposure to 25 microM melphalan and an increased adhesion of monocytes to the epithelial cells in vitro.In conclusion, we have demonstrated that alkylating compounds not only cause cell death of lung epithelial cells but also activate stress-associated MAPK signal transduction pathways and induce expression of mediators known to participate in the recruitment of inflammatory cells. Melphalan 259-268 tumor necrosis factor Homo sapiens 57-90 16178815-3 2005 An elegant approach to circumvent these problems consists in the local application of TNF in an isolated limb or organ setting, preferentially in the presence of cytostatic and alkylating agents, such as melphalan. Melphalan 204-213 tumor necrosis factor Homo sapiens 86-89 15053862-5 2004 The combination of pNGR-TNF or pRGD-TNF with doxorubicin or melphalan induced stronger effects than single agents. Melphalan 60-69 tumor necrosis factor Homo sapiens 36-39 16767914-3 2003 Recently, Tumor Necrosis Factor (TNFalpha) has been employed at high dosages (3-4 mg) in association to Melphalan and hyperthermia. Melphalan 104-113 tumor necrosis factor Homo sapiens 33-41 16767914-5 2003 A phase I - II study was undertaken in order to assess the MTD of TNFalpha in association to true hyperthermia (41.5 degrees C) and Melphalan. Melphalan 132-141 tumor necrosis factor Homo sapiens 66-74 12388254-1 2003 High-dose TNF with melphalan has significant antitumor activity in regional perfusion of the limbs and liver in human malignancies. Melphalan 19-28 tumor necrosis factor Homo sapiens 10-13 12850194-6 2003 They have identified TNFalpha-mediated vasculotoxic effects on the tumour vasculature and have shown that addition of TNFalpha to the perfusate results in an increase of three to six times in uptake of melphalan or doxorubicin by tumours. Melphalan 202-211 tumor necrosis factor Homo sapiens 21-29 12850194-6 2003 They have identified TNFalpha-mediated vasculotoxic effects on the tumour vasculature and have shown that addition of TNFalpha to the perfusate results in an increase of three to six times in uptake of melphalan or doxorubicin by tumours. Melphalan 202-211 tumor necrosis factor Homo sapiens 118-126 11389822-6 2001 High-dose TNF destructs tumor vasculature, and, most importantly, it enhances tumor-selective drug uptake (ie, melphalan and doxorubicin) by threefold to sixfold. Melphalan 111-120 tumor necrosis factor Homo sapiens 10-13 11986187-13 2002 CONCLUSIONS: A good correlation between RISA leakage measurement and TNF alpha exposure during and after hyperthermic isolated limb perfusion with TNF alpha and melphalan was demonstrated. Melphalan 161-170 tumor necrosis factor Homo sapiens 69-78 11417986-13 2001 This may be caused by increased thermal enhancement of melphalan due to the higher tissue temperatures (39--40 degrees C) at which the melphalan in the TNF alpha-ILPs was administered or by an interaction between high-dose TNF alpha and melphalan. Melphalan 55-64 tumor necrosis factor Homo sapiens 152-161 11417986-13 2001 This may be caused by increased thermal enhancement of melphalan due to the higher tissue temperatures (39--40 degrees C) at which the melphalan in the TNF alpha-ILPs was administered or by an interaction between high-dose TNF alpha and melphalan. Melphalan 55-64 tumor necrosis factor Homo sapiens 223-232 10100597-5 1999 TNF was delivered as a 24-h intravenous infusion, 48 h prior to the combination of L-PAM and WBH; L-PAM was given over 10 min at target temperature at a dose of 17.5 mg/ m2 based on a previous phase I WBH/L-PAM trial. Melphalan 83-88 tumor necrosis factor Homo sapiens 0-3 11309322-2 2001 However, the contribution of TNF to the efficacy of isolation perfusion with melphalan has not been demonstrated conclusively in random assignment trials. Melphalan 77-86 tumor necrosis factor Homo sapiens 29-32 9809994-15 1998 The scattered tumor cell necrosis in the latter type may be explained by a TNF-alpha-induced increase in permeability of the tumor vascular bed, which results in higher intratumoral concentrations of melphalan or in a prolongation of its effect. Melphalan 200-209 tumor necrosis factor Homo sapiens 75-84 9621525-2 1998 Several studies have shown that when TNF is used with melphalan in closed circuit perfusion treatment for multiple melanoma metastases confined to a limb, a response rate of 80% can be achieved compared to a best response rate of 40% with melphalan alone. Melphalan 54-63 tumor necrosis factor Homo sapiens 37-40 9621525-2 1998 Several studies have shown that when TNF is used with melphalan in closed circuit perfusion treatment for multiple melanoma metastases confined to a limb, a response rate of 80% can be achieved compared to a best response rate of 40% with melphalan alone. Melphalan 239-248 tumor necrosis factor Homo sapiens 37-40 9166943-0 1997 Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Melphalan 98-107 tumor necrosis factor Homo sapiens 42-51 9166943-1 1997 In this study we determined the level of tumour necrosis factor alpha (TNF-alpha) in liver and tumour tissue samples obtained from patients with colorectal metastases confined to the liver, who were treated with isolated liver perfusion with TNF-alpha and melphalan. Melphalan 256-265 tumor necrosis factor Homo sapiens 71-80